Publications
- Léčba pokročilého a metastazujícího nemalobuněčného karcinomu plic bez řídicích mutací2023 | First Faculty of Medicine
- Atezolizumab in the first-line treatment of non-small cell lung cancer - the IMpower110 trial2022 | First Faculty of Medicine
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- What approach to ALK-positive NSCLC?2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Targeted treatment of bronchogenic carcinoma2020 | First Faculty of Medicine
- Clinical dilemma of lung cancer treatment with anti-PD-1 therapy (nivolumab) in the discovery of rheumatological problems with joint swelling - case report2020 | First Faculty of Medicine
- Lorlatinib in the treatment of non-small cell lung cancer2020 | First Faculty of Medicine
- First-line pembrolizumab for metastatic non-small-cell lung cancer2020 | First Faculty of Medicine
- Atezolizumab ve druhé linii léčby nemalobuněčného plicního karcinomu2020 | First Faculty of Medicine
- Effect of clinical parameters on second- and third-line erlotinib treatment of EGFR wild type patients with advanced NSCLC2019 | First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Central Library of Charles University
Loading network view...